COMMUNIQUÉS West-GlobeNewswire

PCI Biotech: Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital
05/09/2017
Oslo (Norway), 5 September 2017 - Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital in PCI Biotech Holding ASA (the "Company"). 1. Options exercised and [...]
Diaxonhit : acquisition définitive la société GENBIO aux Etats-Unis
05/09/2017
DIAXONHIT acquiert la société GENBIO aux Etats-Unis Réalisation de l'acquisition stratégique d'une entreprise commerciale pour accélérer le développement du groupe aux Etats-Unis et à l'international GENBIO, une société [...]
VALNEVA : Déclaration d'actions et de droits de vote - août 2017
05/09/2017
VALNEVA Déclaration d'actions et de droits de vote - AOUT 2017 Dénomination sociale : VALNEVA Adresse du siège social : World Trade Center Lyon - Tour Oxygène, 10-12 Boulevard Marius Vivier Merle, 69003 Lyon Marché [...]
DBV Technologies : Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social
05/09/2017
Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) Place de cotation : NYSE Euronext [...]
DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company
05/09/2017
Monthly information regarding the total number of voting rights and total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris [...]
Medtronic Launches Long Term Clinical Study Program of INFUSE Bone Graft in Two Common Spine Procedures: PLF and TLIF
05/09/2017
First Patient Enrolled in Initial Posterolateral Fusion Study DUBLIN - September 5, 2017 - Medtronic plc (NYSE: MDT) today announced the launch of a long term clinical study program to collect prospective data on INFUSE [...]
Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia® in the US
05/09/2017
Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia ® in the US Zykadia ® (ceritinib) is an approved treatment for patients with metastatic non-small cell lung cancer (NSCLC) [...]
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
05/09/2017
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]
Auris Medical to Host Scientific Symposium at the AAO-HNSF Annual Meeting
05/09/2017
ZUG, Switzerland, Sept. 5, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, [...]
Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
05/09/2017
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard W. Pascoe, [...]
Summit Therapeutics plc : Positive Top-line Phase 2 Results
05/09/2017
Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT ANNOUNCES POSITIVE TOP-LINE DATA FROM AN EXPLORATORY PHASE 2 CLINICAL TRIAL SUPPORTING RIDINILAZOLE AS A HIGHLY SELECTIVE ANTIBIOTIC FOR THE TREATMENT OF CDI [...]
Helsinn Investment Fund: MAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round
05/09/2017
AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund Funds will be [...]
Ascom appoints Ljubisav Matejevic as Vice President Global Ecosystem & Central and Eastern Europe
05/09/2017
Ascom strengthens its management team by appointing Ljubisav Matejevic as Vice President Global Ecosystem & Central and Eastern Europe (CEE). He will be responsible for Sales Team Leadership, Market Development and [...]
Zealand Pharma to present at Morgan Stanley Global Healthcare Conference in New York on September 12, 2017
05/09/2017
Company announcement - No. 44 / 2017 Zealand Pharma to present at Morgan Stanley Global Healthcare Conference in New York on September 12, 2017 Copenhagen, September 5, 2017 - Britt Meelby Jensen, President and Chief [...]
Glasses go 'bio'. Partnership between Bio-on and Kering Eyewear.
05/09/2017
The two companies will work together on new eco-sustainable materials to match and exceed the characteristics of the plastics used to date in eyewear The aim is to create a series of innovative materials to broaden [...]
Les lunettes deviennent «bio». Avènement d'un partenariat entre Bio-on et Kering Eyewear.
05/09/2017
Les deux entreprises étudieront ensemble de nouveaux matériaux éco-durables, dont les caractéristiques sont comparables, voire supérieures, à celles des matières plastiques utilisées jusqu'à présent dans le secteur de [...]
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
05/09/2017
Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a There is a significant unmet need for safe and effective MS [...]
TiGenix obtains commercial production license for expanded manufacturing facility
05/09/2017
PRESS RELEASE TiGenix obtains commercial production license for expanded manufacturing facility - Provides capacity for potential European commercial roll out of investigational stem cell therapy, Cx601 - Expanded [...]
TiGenix obtient la licence de production commerciale pour son centre de fabrication élargi
05/09/2017
COMMUNIQUÉ DE PRESSE TiGenix obtient la licence de production commerciale pour son centre de fabrication élargi - Le centre a une capacité suffisante pour la commercialisation éventuelle en Europe du Cx601, une thérapie [...]

Pages